zurück Home Ergebnisse beim Endometrium-Karzinom
allgemeines  
Operation
MRC ASTEC Trial pelvine Lymphonodektomie beim Stadium FIGO I: kein Benefit
ILIADE Trial Piver II oder Piver II-Hystektomie beim Stadium FIGO I: kein signifikanter Unterschied
GOG LAP2 Laparotomie v. Laparoskopie  
GOG 33 FIGO I ,II: Hysterektomie mit Adnexen und pelviner Lymphonodektomie, Spülzytologie
EORTC 55962 A randomized phase III trial for evaluation of usefullness of pelvic drains after radical hysterectomy and node dissection (RHND)
LSK-Studie  
RT post OP
PORTEC-1 operiertes Endometrium - Ca FIGO IB/C RT des pelvinen LA versus keine RT
PORTEC-2 operiertes Endometrium - Ca FIGO I/IIa high/intermediate risk 3x7Gy vaginale Brachytherapie versus 46 Gy perkutan
GOG 99 OP +- Nachbestrahlung (4)  
RTOG 12-03 IMRT A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP Study Open Phase III
Chemotherapie post OP
EORTC 55102OP +- Paclitaxel-Carboplatin A phase III Trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. offene Studie
RCh post OP
PORTEC-3 Bei Frauen mit operiertem Hochrisiko - Endometrium - Karzinom kann mit einer postoperativen Radio -Chemotherapie das Gesamtüberleben (nicht signifikant) und das rezidivfreie Überleben (p=0,022) gegenüber einer alleinigen Strahlentherapie verbessert werden.  
EORTC 55991 postoperativ RT versus Radiochemotherapie A randomised trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high risk endometrial carcinoma.
RTOG0973-GOG0238 postoperativ RT versus Radiochemotherapie 0973 GOG-0238/Endorsed Study: "A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus" Open II R.
RTOG1073 -GOG0258 postoperativ Carboplatin - Paclitaxel versus Radiochemotherapie 1073 GOG-0258/Endorsed Study: "A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma" Open III
RTOG 09-21 IMRT - Cisplatin-Bevacizumab, Carboplatin-Paclitaxel A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed By Carboplatin and Paclitaxel For Patients with Endometrial Cancer Closed Phase II
RTOG 04-18 IMRT +- Chemotherapie 0418 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/ Chemotherapy for Postoperative Patients with either Endometrial or Cervical Carcinoma Closed Phase II
RTOG 97-08 RT + Cisplatin/Taxol 9708 A Phase II Study of Adjuvant Postoperative Irradiation Combined with Cisplatin/Taxol chemotherapy Following TAH/BSO for Patients with High-Risk Endometrial Cancer Terminated II
NSABP 99-05 RT +- Cisplatin-Paclitaxel 9905 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Paclitaxel Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Terminated III
primäre RCh RTOG 0417 primäre Radiochemotherapie mit Cisplatin und Bevacizumab A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma. Schefter T, Moughan J, Kwon JS, Stuhr K, Rotman M, Yaremo BP, Small W, Gaffney D, ASCO 2010
nur Chemotherapie
AGO Uterus-4 Docetaxel beim rezidivierten oder metastasierten Endometrium - Ca Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer. Nicht randomisiert, daher kein Nachweis einer Wirksamkeit.
EORTC 55984 AP versus TAP - Chemotherapie beim metastasierten, rezidivierten und inoperablen Endometrium - Karzinom. A randomized trial of adriamycin (A), cisplatin(P) versus paclitaxel (T), adriamycin (A) and cisplatin (P) in patients with metastatic/relapsed or locally advanced inoperable endometrial cancer.
GOG 184 Advanced Stage III-IV Doxorubicin und Cisplatin +- Paclitaxel
GOG 122 Advanced Stage III-IV (1) randomized to whole abdominal XRT vs doxorubicin-cisplatin. o ASCO Abstract 2003 - "Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group" Randall ME et al.
GOG 0086-M liposomales Doxorubicin liposomales Doxorubicin: geringe Wirksamkeit, hohe Haematotoxizität
GOG-209   GOG-209 Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125: 771-3, 2012. (Abstract) Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M, Zaino R
EORTC 55872 adriamycin +- Cisplatin Randomized phase II protocol to study adriamycin/Cisplatin in combination and adriamycin alone in patients with advanced and/or recurrent endometrial carcinoma
EORTC 55873 Cyclophosphamide oder Ifosfamide Randomized phase II protocol to study cyclophosphamide or Ifosfamide in patients with advanced and/or recurrent endometrial carcinoma
EORTC 55853 Carboplatin Phase II trial of carboplatin in advanced/recurrent endometrial carcinoma
EORTC 55839 Mitoxantrone Phase II Chemotherapy with Mitoxantrone for Recurrent and/or Disseminated Endometrial Carcinoma
EORTC 55112 Aromatase IH Efficacy of inhibitors in primary advanced or recurrent endometrial stromal sarcoma : a phase II trial.
endokrine Therapie Gestagene GOG-211 GOG-211 Histologic effects of short term progestins on endometrioid adenocarcinoma: a Gynecologic Oncology Group study. Mod Pathol 23: 270A, 2010. (Abstract) Not Available Not Available Zaino RJ, Brady W, Todd W, Leslie K, Fischer E, Ball H
Fulvestrant GOG-188 GOG-188 Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 120(2): 185-8, 2011. Click Here Click Here Covens AL, Filiaci V, Gersell D, Lutman CV, Bonebrake A, Lee YC
Target - Therapie Temsirolimus GOG-248 (5) Hormonal therapy plus temsirolimus for endometrial carcinoma
Thalidomid GOG-229B GOG-229B A phase II trial of thalidomide in patients with persistent or recurrent endometrial cancer with translational research: a Gynecologic Oncology Group study. Gynecol Oncol 105(2): 508-16, 2007. Here McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD
Gefitinib GOG-229C GOG-229C A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 129(3): 486-94, 2013. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Schilder RJ, Singh M, Maihle NJ
Lapatinib GOG-229D GOG-229D Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 127(2): 345-50, 2012. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG
Bevacizumab GOG-229E GOG-229E Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29(16): 2259-65, 2011. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK
Aflibercept GOG-229F GOG-229F A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 127(3): 538-43, 2012. Click Here Click Here Coleman RL, Sill MW, Lankes HA, Nickles Fader A, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh K, Sood AK
Bevacizumab und Temsirolimus GOG-229G GOG-229G Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 129(1): 22-7, 2013. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn D, Harrison CR, Moore K, Aghajanian C
MEK-1/2 inhibitor GOG-229H GOG-229H A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol : , 2012. (Abstract) (In Press) Coleman RL, Sill MW, Thaker P, Bender DP,De Geest K, Street D, McGuire W, Rotmensch J
Brivanib GOG-229I GOG-229I A phase II trial of brivanib in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Int J Gynecol Cancer 22(8); s3: E115, 2012. (Abstract) Powell MA, Sill MW, Goodfellow PJ, Jeske YW, Leslie KK, Lankes HA, Pollock PM
Histologie serös-papilläres und klarzelliges Endometrium - Ca GOG 94 Bestrahlung des Abdomens, maximales Debulking
EORTC 55961 55961 EORTC 55961,Phase II study on Paclitaxel in recurrent uterine papillary serous carcinoma (UPSC)
GOG 210 Molecular Staging Study of Endometrial Cancer Uterine serous carcinoma: Increased familial risk for Lynch-associated malignancies. Can Prev Res 5(3): 435-43, 2012. Dewdney SB, Kizer NT, Andaya AA, Babb SA, Luo LJ, Mutch DG, Schmidt AP, Brinton LA, Broaddus RR, Ramirez NC, Huettner PC, McMeekin DS, Darcy K, Ali S, Judson PL, Mannel RS, Lele SB, O'Malley DM, Goodfellow PJ A GOG210 ACGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome. Genes Chromosomes Cancer 49: 791-802, 2010. Morrison C, Miecznikowski J, Darcy KM, Dolce JM, Kandel E, Erwin DO, Liu S, Shepherd L, Cohn D, McMeekin DS, Block AW, Nowak NJ, Maxwell L Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 129: 277-84, 2013. Here Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs, LS, Soslow RA, Zaino R

blauer Punkt

1.) Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA.
Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
J Clin Oncol 24 (2006): 36-44

2. Creutzberg CL, van Putten WLJ, Koper PCM, Lybeert MLM, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KAJ, Lutgens LCHW, van den Bergh ACM, van de Steen-Banasik E, Beerman H, van Lent M, for the PORTEC Study Group.
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial.
The Lancet 2000; 355: 1404-1411

3. Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van Lent M, Creutzberg CL; PORTEC Study Group.
Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.
Int J Radiat Oncol Biol Phys 2005; 63: 834-838

4.) Keys HM, Roberts JA, Brunetto VL, et al:
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study.
Gynecol Oncol 92(2004):744-751

5.) Fleming GF, et al.:
Hormonal therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248.
J Clin Oncol 29(2011): 15s, ASCO #5014: 335s (Abstract)


Impressum                         Zuletzt geändert am 26.05.2015 22:18